Biotech ETFs surge ahead of 2026 as Fed cuts boost small-cap sector

In a year when the broader healthcare sector has largely underwhelmed investors, with the largest related ETF posting a modest 11.39% gain, biotechnology stocks and their associated exchange-traded funds (ETFs) have showcased notable strength. Among these, the ALPS Medical Breakthroughs ETF (SBIO) stands out, quietly climbing towards its 52-week highs and delivering a year-to-date gain approaching 43% as of mid-November 2025, according to ETF Trends. This performance significantly outpaces the overall healthcare sector and underscores the potential embedded in smaller biotech stocks, the primary focus of SBIO.

SBIO’s investment approach distinctly targets small- and mid-cap biotech companies that are further along in their development pipeline, specifically those with at least one drug in advanced clinical trial stages (Phase II or III). This strategy helps mitigate some of the risks typically associated with biotech firms that are often cash-intensive and not yet profitable. By mandating that portfolio firms maintain sufficient liquidity to endure extended operational periods, SBIO aims to balance growth potential with financial stability.

The fund’s outperformance in 2025 is also reflective of broader market dynamics, especially in the context of Federal Reserve policy adjustments. The Fed’s two interest rate cuts this year have been instrumental in improving the outlook for smaller biotech firms. Lower interest rates reduce borrowing costs, potentially spurring increased merger and acquisition (M&A) activity in the sector. This is a critical factor as many biotech companies face the challenge of patent expirations and the imperative to replenish their drug pipelines either through internal development or external innovation via acquisitions.

Industry experts from Morgan Stanley have noted these trends. Terence Flynn highlighted that patent expiry is an inherent part of the drug development lifecycle, emphasizing that this cycle intensifies the focus on innovation pipelines and M&A transactions. Flynn observed a recent uptick in deal activity within the small- and mid-cap biotech sphere, which could bode well for the financial performance of this segment. Sean Laaman of Morgan Stanley further pointed out that biotech tends to be one of the best-performing sectors in the six to twelve months following the Fed’s first rate cut, driven by heightened pipeline investment and consolidation.

Supporting this perspective, data from ALPS Funds show that SBIO has been benefiting not just from macroeconomic factors but also from specific sector developments. The fund gained 17.16% year-to-date as of early October 2025, with a robust net asset value (NAV) increase of 11.49% in the preceding month, as detailed by ALPS. This performance can be attributed in part to the catalytic effects of late-stage drug trial successes and sustained M&A momentum. The S-Network Medical Breakthroughs Index, which SBIO tracks, has consistently outperformed benchmarks like the NASDAQ Biotechnology Index, further legitimizing the fund’s targeted approach.

From a risk-return perspective, the biotech segment represented in SBIO exhibits higher volatility, one-year volatility stands at around 32.65%, somewhat above average for equity ETFs, but this is balanced by strong cumulative returns, including nearly 50% over three years. The fund’s top holdings feature companies such as Axsome Therapeutics Inc., Nuvalent Inc., Alkermes Plc, Avidity Biosciences Inc., and Cytokinetics Inc., all of which are engaged in advancing promising medical therapies.

Looking forward to 2026, the prevailing sentiment among analysts is cautiously optimistic. Should the Federal Reserve continue its accommodative stance and maintain or further lower interest rates, this could foster additional M&A activity and pipeline investments within the biotech sector. Given the sensitive relationship between monetary policy and biotech valuations, the SBIO ETF is well positioned to capitalise on these dynamics, providing an accessible vehicle for investors seeking exposure to innovation-driven growth within healthcare.

While the fund’s focus on smaller to mid-sized biotech firms inherently involves elevated risks, including clinical trial uncertainties and market volatility, the combination of robust sector fundamentals, strategic selection criteria, and favourable economic conditions underpin its promising outlook. Investors considering exposure to SBIO, or the biotech sector more broadly, would be well advised to monitor interest rate trends and industry consolidation developments closely.

VettaFi, the index provider for SBIO, clarifies that it receives an index licensing fee but is not involved in the ETF’s management or marketing, a detail that helps maintain transparency around the product’s governance.

In summary, despite a generally disappointing healthcare sector performance in 2025, biotech stocks within the SBIO ETF have bucked the trend with substantial gains driven by late-stage drug development and increasing M&A activity, set against a backdrop of easing monetary policy. This mix of factors points to a potentially robust biotech sector performance in 2026, making SBIO an ETF to watch for investors seeking growth in healthcare innovation.